Literature DB >> 25937830

Protecting the Health and Safety of Cell and Tissue Donors.

David F Stroncek1, Lee England1.   

Abstract

Centers involved with collecting the starting material for cell and tissue therapies are obligated to protect the recipient's and donor's health and safety. All donors face risks during and after the collection which can be minimized by prescreening donors and excluding those that the collection would place at increased risk of physical harm. Another important part of protecting donors is the use of appropriate collection facilities. Donor risk can also be reduced by using specially designed collection devices and ancillary equipment, using only trained collection staff and limiting the volume or quantity of biologic material collected. Donors should be monitored during and after the collection for adverse events, and should adverse events occur, they should be promptly and appropriately treated. Protecting the safety of cell, gene and tissue donors is particularly difficult because of the wide variety in the types of donors and material collected. Biological material used to manufacture cell and tissue therapies is collected from healthy volunteers, matched-related, matched-unrelated and autologous donors. Precautions should be taken to ensure that the team of medical professionals evaluating related donors is not the same as the team caring for the transplant recipient in order to be sure that the donor evaluation is not biased and the donor is not coerced into donating. In conclusion, protecting cell and tissue donors requires the use of the practices developed to protect blood donors and the implementation of many other measures.

Entities:  

Keywords:  Cellular therapies; apheresis; donations; donors; marrow aspiration; marrow donation

Year:  2015        PMID: 25937830      PMCID: PMC4414045          DOI: 10.1111/voxs.12150

Source DB:  PubMed          Journal:  ISBT Sci Ser        ISSN: 1751-2816


  22 in total

1.  Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues.

Authors:  Jeffrey McCullough; Jeffrey Kahn; John Adamson; Paolo Anderlini; Richard Benjamin; Dennis Confer; Mary Eapen; Betsy Hirsch; David Kuter; Ellen Lazarus; Derwood Pamphilon; David Stroncek; Jeremy Sugarman; Robert Wilson
Journal:  Transfusion       Date:  2008-06-28       Impact factor: 3.157

Review 2.  Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.

Authors:  Bronwen E Shaw; Dennis L Confer; William Y Hwang; Derwood H Pamphilon; Michael A Pulsipher
Journal:  Haematologica       Date:  2011-07       Impact factor: 9.941

Review 3.  Current clinical indications for plerixafor.

Authors:  Stefan Fruehauf
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

4.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers.

Authors:  A P Grigg; A W Roberts; H Raunow; S Houghton; J E Layton; A W Boyd; K M McGrath; D Maher
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

5.  Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations.

Authors:  B E Shaw; L Ball; M Beksac; M Bengtsson; D Confer; S Diler; M Fechter; H Greinix; M Koh; S Lee; G Nicoloso-De-Faveri; J Philippe; S Pollichieni; M Pulsipher; A Schmidt; E Yang; A-M van Walraven
Journal:  Bone Marrow Transplant       Date:  2010-02-22       Impact factor: 5.483

6.  Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells.

Authors:  D F Stroncek; M E Clay; M L Petzoldt; J Smith; W Jaszcz; F B Oldham; J McCullough
Journal:  Transfusion       Date:  1996-07       Impact factor: 3.157

7.  Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program.

Authors:  D F Stroncek; P V Holland; G Bartch; T Bixby; R G Simmons; J H Antin; K C Anderson; R C Ash; B J Bolwell; J A Hansen
Journal:  Blood       Date:  1993-04-01       Impact factor: 22.113

8.  Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Bronwen E Shaw; John R Wingard; Hillard M Lazarus; Edmund K Waller; Matthew Seftel; David F Stroncek; Angela M Lopez; Dipnarine Maharaj; Peiman Hematti; Paul V O'Donnell; Alison W Loren; Susan F Leitman; Paolo Anderlini; Steven C Goldstein; John E Levine; Willis H Navarro; John P Miller; Dennis L Confer
Journal:  Blood       Date:  2012-10-29       Impact factor: 22.113

9.  Long-term safety of filgrastim (rhG-CSF) administration.

Authors:  Dennis L Confer; John P Miller
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998

10.  Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF.

Authors:  David F Stroncek; Kristin Dittmar; Thomas Shawker; Angela Heatherman; Susan F Leitman
Journal:  J Transl Med       Date:  2004-07-21       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.